{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=51",
    "query": {
      "condition": "Pharmacokinetics and Pharmacodynamics",
      "page": 51
    },
    "page_size": 10
  },
  "pagination": {
    "page": 51,
    "page_size": 10,
    "total_count": 2341,
    "total_pages": 235,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=52&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=50&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T15:50:06.134Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03676231",
      "title": "Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "SGM-1019",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Second Genome",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 9,
      "start_date": "2019-01-18",
      "completion_date": "2019-05-01",
      "has_results": false,
      "last_update_posted_date": "2019-07-11",
      "last_synced_at": "2026-10-20T15:50:06.134Z",
      "location_count": 10,
      "location_summary": "Chandler, Arizona • Tucson, Arizona • Panorama City, California + 7 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Panorama City",
          "state": "California"
        },
        {
          "city": "Lakewood Rch",
          "state": "Florida"
        },
        {
          "city": "Flowood",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03676231"
    },
    {
      "nct_id": "NCT04504669",
      "title": "First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clear Cell Renal Cell Cancer",
        "Non-Small-Cell Lung Cancer",
        "Triple Negative Breast Neoplasms",
        "Squamous Cell Cancer of Head and Neck",
        "Small Cell Lung Cancer",
        "Gastroesophageal Cancer",
        "Melanoma",
        "Cervical Cancer",
        "Advanced Solid Tumours"
      ],
      "interventions": [
        {
          "name": "AZD8701",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "101 Years",
        "sex": "ALL",
        "summary": "18 Years to 101 Years"
      },
      "enrollment_count": 60,
      "start_date": "2020-08-18",
      "completion_date": "2024-10-07",
      "has_results": false,
      "last_update_posted_date": "2024-11-05",
      "last_synced_at": "2026-10-20T15:50:06.134Z",
      "location_count": 6,
      "location_summary": "Baltimore, Maryland • St Louis, Missouri • Huntersville, North Carolina + 3 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        },
        {
          "city": "Franklin",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04504669"
    },
    {
      "nct_id": "NCT05702983",
      "title": "The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Antineutrophil Cytoplasmic Antibody Associated Vasculitis"
      ],
      "interventions": [
        {
          "name": "STSA-1002 subcutaneous injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Staidson (Beijing) Biopharmaceuticals Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "57 Years",
        "sex": "ALL",
        "summary": "21 Years to 57 Years"
      },
      "enrollment_count": 20,
      "start_date": "2023-01-31",
      "completion_date": "2023-04-24",
      "has_results": false,
      "last_update_posted_date": "2023-05-26",
      "last_synced_at": "2026-10-20T15:50:06.134Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05702983"
    },
    {
      "nct_id": "NCT04684654",
      "title": "BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants",
        "Primary Sjögren's Syndrome"
      ],
      "interventions": [
        {
          "name": "BMS-986325",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for BMS-986325",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 118,
      "start_date": "2021-02-16",
      "completion_date": "2023-07-25",
      "has_results": false,
      "last_update_posted_date": "2023-08-23",
      "last_synced_at": "2026-10-20T15:50:06.134Z",
      "location_count": 1,
      "location_summary": "Covina, California",
      "locations": [
        {
          "city": "Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04684654"
    },
    {
      "nct_id": "NCT03095651",
      "title": "Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus",
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "MK-5160 16 nmol/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MK-5160 32 nmol/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MK-5160 64 nmol/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Glargine 0.4 U/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to Glargine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to MK-5160",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dextrose",
          "type": "DRUG"
        },
        {
          "name": "Glargine 0.6 U/kg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 33,
      "start_date": "2017-04-12",
      "completion_date": "2018-01-30",
      "has_results": true,
      "last_update_posted_date": "2019-04-01",
      "last_synced_at": "2026-10-20T15:50:06.134Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03095651"
    },
    {
      "nct_id": "NCT00858962",
      "title": "Buprenorphine/Raltegravir Pharmacokinetic Interaction Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infection",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Raltegravir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "21 Years to 60 Years"
      },
      "enrollment_count": 12,
      "start_date": "2009-03",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2012-11-21",
      "last_synced_at": "2026-10-20T15:50:06.134Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00858962"
    },
    {
      "nct_id": "NCT02159859",
      "title": "Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Ertapenem",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corewell Health East",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "88 Years",
        "sex": "ALL",
        "summary": "18 Years to 88 Years"
      },
      "enrollment_count": 7,
      "start_date": "2014-12",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2018-10-17",
      "last_synced_at": "2026-10-20T15:50:06.134Z",
      "location_count": 1,
      "location_summary": "Dearborn, Michigan",
      "locations": [
        {
          "city": "Dearborn",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02159859"
    },
    {
      "nct_id": "NCT04691570",
      "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Warm Autoimmune Hemolytic Anemia (wAIHA)"
      ],
      "interventions": [
        {
          "name": "ANX005",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Annexon, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2021-11-10",
      "completion_date": "2023-01-17",
      "has_results": true,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-10-20T15:50:06.134Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04691570"
    },
    {
      "nct_id": "NCT01545570",
      "title": "A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "GSK2376497",
          "type": "DRUG"
        },
        {
          "name": "0.9% sodium chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 82,
      "start_date": "2011-11-07",
      "completion_date": "2012-12-23",
      "has_results": false,
      "last_update_posted_date": "2017-07-25",
      "last_synced_at": "2026-10-20T15:50:06.134Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01545570"
    },
    {
      "nct_id": "NCT01129258",
      "title": "Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus",
        "Diabetes Mellitus, Type 2",
        "Glucose Metabolism Disorders"
      ],
      "interventions": [
        {
          "name": "PF-04991532",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 110,
      "start_date": "2010-06",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2011-03-09",
      "last_synced_at": "2026-10-20T15:50:06.134Z",
      "location_count": 4,
      "location_summary": "Chula Vista, California • Fountain Valley, California • Miami, Florida + 1 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01129258"
    }
  ]
}